Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice

Multiple Sclerosis Journal

Volumn 18, Issue 12, 2012, Pages 1775-1781

  Jungedal, Roger ^a   Lundkvist, Malin ^a   Engdahl, Elin ^a   Ramanujam, Ryan ^a   Westerlind, Helga ^a   Sominanda, Ajith ^b   Hillert, Jan ^a   Fogdell Hahn, Anna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF PERADENIYA   (Sri Lanka)

Author keywords

anti drug antibodies (ADAs); Immunogenicity; interferon beta; multiple sclerosis; neutralizing antibodies; seroprevalence

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CLINICAL PRACTICE; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; SEROPREVALENCE; TREATMENT DURATION;

EID: 84871575939     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512446036     Document Type: Article

References (28)

1. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995 ; 45: 1277-1285
2. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology. 1998 ; 50: 1266-1272
3. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001 ; 56: 1628-1636
4. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: Prevalence and impact on outcomes. CNS Drugs. 2009 ; 23: 379-396
5. Larocca AP, Leung SC, Marcus SG, et al. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res. 1989 ; 9: S51 - S60
6. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000 ; 48: 706-712
7. Gibbs E, Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol. 2007 ; 190: 146-150
8. Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology. 2005 ; 65: 33-39
9. Petersen B, Bendtzen K, Koch-Henriksen N, et al. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006 ; 12: 247-252
10. Sominanda A, Hillert J, Fogdell-Hahn A. Neutralizing antibodies against interferon beta: Fluctuation is modest and titre dependent. Eur J Neurol. 2009 ; 16: 21-26
11. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology. 1998 ; 51: 1698-1702
12. Gneiss C, Koudouovoh-Tripp PM, Ropele S, et al. Influence of interferon-beta therapy switching on neutralizing antibody titres: Results from the Austrian Switch Study. Mult Scler. 2009 ; 15: 1481-1488
13. Massart C, Gibassier J, Oger J, et al. Neutralizing antibodies to interferon beta in multiple sclerosis: Analytical evaluation for validation of a cytopathic effect assay. Clin Chim Acta. 2007 ; 377: 185-191
14. Bertolotto A, Sala A, Caldano M, et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods. 2007 ; 321: 19-31
15. Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler. 2008 ; 14: 212-218
16. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 57-62
17. Sominanda A, Rot U, Suoniemi M, et al. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler. 2007 ; 13: 208-214
18. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009 ; 73: 372-377
19. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
20. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther. 2007 ; 29: 1128-1145
21. Phillips JT, Rice G, Frohman E, et al. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther. 2004 ; 26: 511-521
22. Aarskog NK, Maroy T, Myhr KM, et al. Antibodies against interferon-beta in multiple sclerosis. J Neuroimmunol. 2009 ; 212: 148-150
23. Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol. 2004 ; 251: 305-309
24. Foley P, Reilly P, Coulson A, et al. Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis. J R Coll Physicians Edinb. 2010 ; 40: 105-110
25. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008 ; 70: 1119-1127
26. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology. 1999 ; 53: 679-686
27. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 ; 352: 1498-1504
28. Grossberg SE, Oger J, Grossberg LD, et al. Frequency and magnitude of interferon beta neutralizing antibodies in the evaluation of interferon beta immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res. 2011 ; 31: 337-344